Skip to content
PIL Logo

Alvesco 40, 80 and 160 Inhaler

Last Updated on eMC 05-Jun-2017 View document  | AstraZeneca UK Limited Contact details

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC.  For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 05-Jun-2017 and displayed until Current

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - manufacturer
  • Change to section 6 - date of revision

Updated on 07-Jan-2016 and displayed until 05-Jun-2017

Reasons for adding or updating:

  • Change to section 5 - how to store

Updated on 24-Apr-2015 and displayed until 07-Jan-2016

Reasons for adding or updating:

  • Change to section 6 - date of revision

Updated on 16-Jul-2014 and displayed until 24-Apr-2015

Reasons for adding or updating:

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect

Updated on 18-Dec-2012 and displayed until 16-Jul-2014

Reasons for adding or updating:

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 08-Jun-2011 and displayed until 18-Dec-2012

Reasons for adding or updating:

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 25-Oct-2010 and displayed until 08-Jun-2011

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 31-Aug-2010 and displayed until 25-Oct-2010

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 17-Feb-2010 and displayed until 31-Aug-2010

Reasons for adding or updating:

  • Change due to harmonisation of PIL.
  • Change to Further Information section
  • Change to date of revision
  • Change to side-effects
  • Change to manufacturer contact details

Updated on 17-Apr-2009 and displayed until 17-Feb-2010

Reasons for adding or updating:

  • Change to date of revision
  • Change to side-effects

Updated on 19-Feb-2009 and displayed until 17-Apr-2009

Reasons for adding or updating:

  • Change to date of revision
  • Change of manufacturer

Updated on 15-Jan-2009 and displayed until 19-Feb-2009

Reasons for adding or updating:

  • Transfer to upgraded management system

Updated on 25-Feb-2008 and displayed until 15-Jan-2009

Reasons for adding or updating:

  • Change of licence holder
  • Company name change or merger
  • Change to MA holder contact details
  • Change to date of revision

Updated on 13-Jul-2007 and displayed until 25-Feb-2008

Reasons for adding or updating:

  • Improved Electronic Presentation

Updated on 10-Jul-2006 and displayed until 13-Jul-2007

Reasons for adding or updating:

  • Change to, or new, use for medicine
  • Change to side-effects

Updated on 05-May-2005 and displayed until 10-Jul-2006

Reasons for adding or updating:

  • Change to packaging
  • Change of contra-indications
  • Change to side-effects
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to date of revision

Updated on 28-Apr-2005 and displayed until 05-May-2005

Reasons for adding or updating:

  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to information about driving or using machinery
  • Change to date of revision
  • Change to storage instructions
  • Change to packaging

Updated on 15-Feb-2005 and displayed until 28-Apr-2005

Reasons for adding or updating:

  • New PIL for eMC ie a PIL for an existing product but one that is new to the eMC

Company contact details

AstraZeneca UK Limited

Company image
Address

Horizon Place, 600 Capability Green, Luton, Bedfordshire, LU1 3LU

Fax

+44 (0)1582 838 000

Medical Information e-mail
Medical Information Fax

+44 (0)1582 838 003

Telephone

+44 (0)1582 836 000

Medical Information Direct Line

0800 783 0033

Customer Care direct line

+44 (0)1582 837 837

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Active ingredients

ciclesonide

Legal categories

POM - Prescription Only Medicine

This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Continue